



Final Appraisal Recommendation
Advice No: 3215 – November 2015

Insulin glargine (Abasaglar[®]▼) 100 units/ml solution for injection

Submission by Eli Lilly & Co Ltd

Recommendation of AWMSG

Insulin glargine (Abasaglar[®]▼) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

Insulin glargine (Abasaglar[®]▼) should be prescribed within its licensed indication in accordance with NICE or AWMSG guidance for insulin glargine (Lantus[®]), the reference product.

Insulin glargine (Abasaglar[®]▼) is not recommended for use within NHS Wales outside of these circumstances.

Insulin glargine (Abasaglar[®]▼) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2307), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Boehringer Ingelheim and Eli Lilly & Co Ltd
Date of first issue	November 2015
Last reviewed	March 2019



Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3215:
insulin glargine (Abasaglar[®]) 100 units/ml solution for injection. November 2015.

